Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins ? significance for the patient

Hartinger, C.G.; Hann, S.; Koellensperger, G.; Sulyok, M.; Grössl, Michael; Timerbaev, A.R.; Rudnev, A.V.; Stingeder, G.; Keppler, B.K. (2005). Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins ? significance for the patient. International journal of clinical pharmacology and therapeutics, 43(12), pp. 583-585. Dustri-Verlag 10.5414/CPP43583

Full text not available from this repository. (Request a copy)

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension

UniBE Contributor:

Grössl, Michael

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0946-1965

Publisher:

Dustri-Verlag

Language:

English

Submitter:

Michael Grössl

Date Deposited:

04 Oct 2019 15:17

Last Modified:

04 Oct 2019 15:17

Publisher DOI:

10.5414/CPP43583

PubMed ID:

16372526

URI:

https://boris.unibe.ch/id/eprint/112165

Actions (login required)

Edit item Edit item
Provide Feedback